Lauren E. Matevish

Lauren E. Matevish

Auto-generated profile, based on publicly available information

Lauren E. Matevish

Division of Surgical Transplantation, Department of Surgery, University of Texas Southwestern Medical Center, Dallas, TX

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 April 2024 in Journal of Hepatology
Verified
Journal Article
Closed access
LMLauren E. Matevish
Lauren E. Matevish
PVParsia A. Vagefi
Parsia A. Vagefi
MPMadhukar S. Patel
Madhukar S. Patel

5 July 2025 in American Journal of Transplantation
Verified
Journal Article
Open access
AAAhmad Anouti
Ahmad Anouti
ADAli Dakroub
Ali Dakroub
HKHussein Krayem
Hussein Krayem
LMLauren E. Matevish
Lauren E. Matevish
Hamza DahshiHamza Dahshi
Hamza Dahshi
MPMadhukar S. Patel
Madhukar S. Patel
Simultaneous heart liver transplantation (SHLT) has expanded in recent years, bolstered by increases in congenital heart disease (CHD) indications and improvements in organ preservation. We performed a contemporary analysis of patients undergoing SHLT for CHD vs non-CHD, further exploring the impact of machine perfusion (MP). Patients undergoing SHLT between 2010-2024 were retrospectively identified using the UNOS database, assessing a primary outcome of patient survival and secondary outcome of MP utilization. 535 patients underwent SHLT, 224(41.9%) with CHD indication and 311(58.1%) non-CHD. CHD recipients had significantly lower one-(72.9% vs. 89.4%,p<0.01) and five-year survival (66.1% vs. 81.4%,p<0.01) compared to non-CHD recipients. CHD indication was independently associated with a two-fold increased mortality risk, compared to a non-CHD diagnosis (HR:2.31, 95%CI:[1.53,3.47]). Decision tree boosting demonstrated a 2.9% higher relative mortality likelihood after SHLT for recipients with CHD. From 2022-2024, SHLT MP utilization for CHD increased; among 111 patients, 18.0% received a MP liver, 8.1% a MP heart, and 10.8% MP heart and MP liver. In this analysis of modern SHLT cases, patients with CHD had suboptimal outcomes; several donor and recipient factors also impacted mortality. Awareness of these factors can guide pre-transplant optimization, donor/recipient matching, and strategic MP use to improve survival.

16 September 2025 in Surgery
Verified
Journal Article
Closed access
LMLauren E. Matevish
Lauren E. Matevish
BJBrian Jafari
Brian Jafari
TCTaylor M. Coe
Taylor M. Coe
AMArjmand Mufti
Arjmand Mufti
PVParsia A. Vagefi
Parsia A. Vagefi
MPMadhukar S. Patel
Madhukar S. Patel

28 May 2025 in Annals of Surgery
Verified
Journal Article
Closed access
LMLauren E. Matevish
Lauren E. Matevish
MPMadhukar S. Md Patel
Madhukar S. Md Patel
DRDeepa Bs Ravindra
Deepa Bs Ravindra
JSJigesh A. Do Shah
Jigesh A. Do Shah
DWDavid Do Wojciechowski
David Do Wojciechowski
PVParsia A. Vagefi
Parsia A. Vagefi
Objective: We sought to determine how kidney transplant center volume impacts waitlisted candidate access to transplant. Background: Over 90,000 candidates await a kidney transplant, of which we hypothesized that waitlist access is subject to significant program-level variation, potentially resulting in pseudo-access: a state where the waitlisted candidate does not achieve expected transplantation. Methods: Center-level data on all US adult kidney transplant programs was collected using the Scientific Registry of Transplant Recipients program-specific reports, updated through December 31, 23. Programs (N=196) were stratified into quartiles by yearly deceased donor kidney transplant volume (Q1 lowest, Q4 highest); program acceptance practices and outcomes were compared. Results: Compared with lower volume programs, Q4 programs transplanted a higher proportion of their waitlist (30.5% vs 13.1% for Q1; P <0.001) with a higher transplant rate ratio (1.41 vs 0.74 for Q1; P 1.75: 1.51 vs 0.46 for Q1; P 100 offers: 1.18 vs 0.25 for Q1; P <0.001). Despite increased utilization of more marginal grafts, Q4 programs demonstrated shorter post-transplant hospital lengths of stay [median 4 days (4–5) vs 6 (5–7) for Q1; P <0.001]. Conclusions: High-volume (HV) programs excel through aggressive organ utilization, while low-volume (LV) programs often provide pseudo-access to transplantation, characterized by low transplant rate ratios, conservative offer acceptance practices, and prolonged wait times. To increase kidney allograft utilization, LV programs unable to improve acceptance practices should consider consolidation or the development of access programs to facilitate candidate migration to HV centers.

4 May 2023 in The American Surgeon™
Verified
Journal Article
Open access
JKJoshua Kurian
Joshua Kurian
LMLauren E. Matevish
Lauren E. Matevish
CFCyrus Feizpour
Cyrus Feizpour
JSJigesh A. Shah
Jigesh A. Shah
CHChristine Hwang
Christine Hwang
MPMadhukar S. Patel
Madhukar S. Patel
Background: The proportion of older patients on the liver transplant waitlist continues to increase. With limited existing data to guide liver transplant evaluation of elderly patients, we aimed to study selection practices and outcomes of patients ≥70 years old. We hypothesized that 1-year patient and graft survival would not differ between appropriately selected elderly patients and those who are younger. Methods: All patients referred for liver transplantation between 2018 and 2020 were stratified into elderly (age ≥70) and young (age <70) cohorts. Evaluation data pertaining to medical, surgical, and psychosocial risk assessment were reviewed. Recipient characteristics and post-operative outcomes, primarily 1-year graft and patient survival, were compared, with a median follow-up of 16.4 months. Results: 322 patients underwent transplant out of 2331 referred. Elderly patients represented 230 of these referrals and 20 underwent transplant. The most common reasons for denial of elderly patients were multiple medical comorbidities (49%), cardiac risk (15%) and psychosocial barriers (13%). The median MELD of elderly recipients was lower (19 vs 24, P = .02), and proportion of hepatocellular carcinoma was higher (60% vs 23%, P < .001). There was no difference in 1-year graft (elderly 90.9% vs young 93.3%, P = .72) or patient survival (elderly 90.9% vs young 94.7%, P = .88). Discussion: Liver transplant outcomes and survival are not affected by advanced age in carefully evaluated and selected recipients. Age should not be considered an absolute contraindication for liver transplant referral. Efforts should be made to develop guidelines for risk stratification and donor–recipient matching that optimize outcomes in elderly patients.

6 July 2025 in The American Journal of Surgery
Verified
Journal Article
Closed access
LMLauren E. Matevish
Lauren E. Matevish
JGJason Guo
Jason Guo
YBYanik J. Bababekov
Yanik J. Bababekov
ASAndrew D. Shubin
Andrew D. Shubin
NGNicolas Goldaracena
Nicolas Goldaracena
MPMadhukar S. Patel
Madhukar S. Patel